254 related articles for article (PubMed ID: 24021017)
21. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Kern E; Schmidinger M; Locker GJ; Kopp B
Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983
[TBL] [Abstract][Full Text] [Related]
22. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
23. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
25. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
[TBL] [Abstract][Full Text] [Related]
26. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Zhao C; Chen J; Yu B; Wu X; Dai C; Zhou C; Chen X
J Tradit Chin Med; 2014 Feb; 34(1):10-4. PubMed ID: 25102684
[TBL] [Abstract][Full Text] [Related]
27. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
28. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
[TBL] [Abstract][Full Text] [Related]
29. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Saif MW; Elfiky A; Diasio R
Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
[TBL] [Abstract][Full Text] [Related]
30. [Hand-foot syndrome induced by chemotherapy: a case study].
Simão DA; Lima ED; Souza RS; Faria TV; Azevedo GF
Rev Bras Enferm; 2012; 65(2):374-8. PubMed ID: 22911424
[TBL] [Abstract][Full Text] [Related]
31. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL;
J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036
[TBL] [Abstract][Full Text] [Related]
32. [Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
Kuji M; Masuko H; Yamagami H; Matsumoto S; Tanioka T; Takahashi S; Ishizu H; Takahashi M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1752-4. PubMed ID: 25731318
[TBL] [Abstract][Full Text] [Related]
33. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
34. High frequency of hand foot syndrome with capecitabine.
Kamil M; Haron M; Yosuff N; Khalid I; Azman N
J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
[TBL] [Abstract][Full Text] [Related]
35. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
[No Abstract] [Full Text] [Related]
36. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
37. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Paule I; Tod M; Hénin E; You B; Freyer G; Girard P
Cancer Chemother Pharmacol; 2012 Feb; 69(2):447-55. PubMed ID: 21809035
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine and Hand-foot Syndrome: A Case Report.
Uppala PK; Varghese AM; Yella SST; Velmurugan H; Thangaraju P; Krishna Sasanka KSBS
Infect Disord Drug Targets; 2023; 23(1):e140622205973. PubMed ID: 35708076
[TBL] [Abstract][Full Text] [Related]
39. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of topical
Mohajerani R; Shahi F; Jafariazar Z; Afshar M
Cutan Ocul Toxicol; 2021 Sep; 40(3):257-262. PubMed ID: 34152880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
